Business Context and Reporting Period
This Form 8-K Current Report was filed by Maravai LifeSciences Holdings, Inc. on June 22, 2025. The filing primarily addresses Item 5.02 regarding the departure of a senior officer and the appointment of a new Chief Financial Officer (CFO).
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on executive compensation and personnel changes.
Material Changes
The material change reported is the succession of the Chief Financial Officer:
- Outgoing CFO: Kevin Herde is stepping down from the role effective June 30, 2025.
- Transition Plan: Mr. Herde will provide consulting services in an advisory capacity from June 30, 2025, through January 31, 2026.
- Separation Terms: Mr. Herde is entitled to payments and benefits under his existing employment agreement, subject to the execution of a separation agreement and release of claims.
- Incoming CFO: Rajesh Asarpota has been appointed as CFO, effective June 30, 2025.
Guidance, Outlook, and Compensation Details
The filing details the employment agreement and compensation package for the new CFO, Mr. Asarpota, effective June 30, 2025:
- Base Salary: $550,000 annually.
- Target Bonus: 70% of annual base salary.
- Sign-on Bonus: $200,000 cash, payable within 30 days of the effective date (subject to repayment if terminated for cause or without good reason within the first year).
- Equity Awards:
- 333,333 non-qualified stock options.
- 500,000 restricted stock units (RSUs).
- 750,000 performance stock units (PSUs) tied to volume-weighted average stock price hurdles.
- Vesting Schedule: Options and RSUs vest over three years (one-third on the first anniversary, then monthly). PSUs vest based on performance metrics measured prior to the third anniversary.
- Severance: In the event of a "Qualifying Termination" (without cause or for good reason), Mr. Asarpota is eligible for 12 months of salary plus target bonus, pro-rata bonus, and health coverage. If termination occurs within 24 months of a change in control, severance increases to two times the sum of salary plus target bonus, with full vesting of time-based awards.
Investor Verification Checklist
- Verify the exact terms of the separation agreement for outgoing CFO Kevin Herde to understand potential one-time costs.
- Review the specific stock price hurdles for the 750,000 PSUs granted to the new CFO to assess performance expectations.
- Confirm the total annualized compensation cost for the new CFO, including the sign-on bonus amortization and equity grant value.
- Check for any subsequent filings regarding the transition period or changes to the company's financial reporting timeline due to the leadership change.